Skip to main content

Table 1 Basic characteristics of included studies

From: The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis

Study Year Country Sample size/N mGPS
group
Age (year)(%) Survival
analysis
NOS
score
Tumor stage Therapy Mean
Follow-up
(month)
Research
duration
Partridge et al. [30] 2012 UK 102 (16/20/66) 0/1/2 ≤ 72, (50%) M 6 Advanced Chemotherapy 2006.01–2006.10
Jamieson et al. [32] 2011 UK 135 (74/61) Low/high ≤ 65, (54%) M 6 T2/T3 Pancreatectomy 2002–2009
Torre et al. [29] 2012 Italy 82 (37/45) Low/high M 5 I/IV Chemotherapy 19 2003–2009
Wang et al. [26] 2012 China 177 (115/62) Low/high ≤ 65, (70.1%) U, M 6 II/IV Chemotherapy 31.33 2006–2010
Inoue et al. [25] 2015 Japan 440 (367/49/24) 0/1/2 ≤ 65, (40.7%) U 7 I/IV Chemotherapy 18.7 2008–2012
Martin et al. [27] 2014 Australia 124 (46/78) Low/high U, M 7 Locally advanced
or metastatic
Chemotherapy 12 2008–2012
Mitsunaga et al. [18] 2016 Japan 141 (79/39/23) 0/1/2 ≤ 67, (50%) M 5 Advanced Chemotherapy 2008–2013
Imaoka et al. [38] 2016 Japan 807 (620/153/34) 0/1/2 < 75, (81.9%) U 7 Locally advanced
or metastatic
Chemotherapy   2001–2013
Wu et al. [8] 2016 China 233 (119/114) Low/high < 62, (47.6%) U, M 5 Advanced Chemotherapy 2011–2014
Kawai et al. [17] 2016 Japan 1347 (1121/115/111) 0/1/2 M 6 I/IV Pancreatectomy 25.3 2001–2012
Yamada et al. [33] 2016 Japan 305 (243/62) Low/high ≤ 65, (50.1%) U, M 5 I/IV Chemotherapy 2002–2014
Liu et al. [15] 2017 China 386 (131/242/13) 0/1/2 ≤ 65, (35.8%) U 5 I/IV Chemotherapy 8.7 2010–2015
Iino et al. [24] 2017 Japan 47 (35/12) Low/high U, M 7 Locally advanced
or metastatic
Chemotherapy 2010–2015
Xiao et al. [34] 2017 China 66 (39/27) Low/high U, M 6 Advanced Chemotherapy 2012–2013
Fujjiwara et al. [35] 2018 Japan 188 (140/21/27) 0/1/2 < 70, (54.3%) U, M 8 I/IV Pancreatectomy 2000–2015
Ikuta et al. [36] 2019 Japan 136 (131/5) Low/high ≤ 68, (54.4%) U 5 I/IV Pancreatectomy 16.8 2005–2017
Abe et al. [16] 2018 Japan 329 (282/47) Low/high < 65, (43.76%) U, M 6 I/IV Pancreatectomy 1996–2014
Shin et al. [31] 2018 South
Korea
1092 (587/353/152) 0/1/2 M 6 I/IV Chemotherapy 21.6 2000–2016
Hwang et al. [28] 2018 South
Korea
203 (137/66) Low/high ≤ 65, (62.1%) U, M 8 Metastatic or
recurrent
Chemotherapy 21.5 2016.01-2016.12
Nakagawa et al. [37] 2019 Japan 172 (157/15) Low/high < 70, (49.4%) U, M 6 I/IV Pancreatectomy 2006–2015
  1. “–” means not available; N means number; U means univariable regression analysis; M means multivariable regression analysis